Jörg Überla

Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany.

Jenner & Block LLC provides legal services. It focuses on mergers and acquisitions, securities, finance, private equity, real estate, tax, environmental, insurance, commercial law, technology, intellectual property, bankruptcy and reorganization, labor and employment, executive compensation, government contracts, health care and associations. The company was founded in 1914 and is headquartered in Chicago, IL.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

Apax Partners Beteiligungsberatung GmbH (APB) is a private equity firm located in Munich, Germany. APB is a subsidiary of London-based Apax Partners Holdings Ltd. with the ultimate parent firm being UK-headquartered Apax Partners Worldwide LLP which can trace their history to 1972. In 1972, Ronald Cohen and Maurice Tchenio co-founded the Multinational Management Group (MMG). In 1976, the Alan Patricof Associates firm joined forces with MMG to form Apax Partners. In 2002, the European and the U.S. operating firms merged to become Apax Partners Worldwide LLP, headquartered in London. They also operate through offices in New York, Madrid, Milan, Paris, Stockholm, Mumbai, Tel Aviv and Hong Kong. In 2005, the Apax Foundation was established for the group's charitable donations. The foundation supports entrepreneurial endeavors, social investment and educational initiatives aimed at alleviating poverty worldwide.

BridgeCo, a networked entertainment pioneer, offers the world’s most comprehensive, cost-effective and highly integrated processor IC and software platforms for connecting Internet media sources, computers and consumer electronics throughout the home. BridgeCo platforms are targeted at the multi-billion dollar global market for stand-alone after-market and embedded audio applications. BridgeCo platforms are the core technologies underlying digital media players (DMPs), audio/video receivers (AVRs), musical instruments and external multi-channel sound cards.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

adviqo GmbH engages in the provision of information, content management, and consulting services. Its product include in the segments of life coaching, television channels, content and shopping-based online products, and magazine and brochures. The firm's brands include Questico, Fortunica, AstroTV, The Circle, and Noe astro. Its business model provides people with different communication and consumer behavior the opportunity to find the right products and services to match their spiritual needs. The company was founded by Sylvius Bardt and Dieter Lang on April 4, 2000 and is headquartered in Berlin, Germany.

New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY.

AUCTUS Capital Partners AG (AUCTUS) is an independent, management-owned German private equity firm which was founded in 2001 and is headquartered in Munich, Germany.

Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

btov Partners AG (btov) is a venture capital firm founded in 2000 by St. Gallen University students as an online job platform BrainsToVentures, with backing from Swiss business angels. The firm is headquartered in St. Gallen, Switzerland.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

APEIRON Biologics AG operates as a clinical-stage company which engages in the discovery and development of novel cancer immunotherapies. The firm develops APN311, a therapeutic antibody to treat pediatric patients with neuroblastoma; APN301, an immunocytokine consisting of a humanized antibody genetically linked to two human IL-2 molecules; and APN401, a first-in-class autologous cellular therapy. The company was founded by Josef Penninger in 2005 and is headquartered in Vienna, Austria.

Orcan Energy AG develops solutions for the optimization of energy efficiency in industrial processes and engine systems. It offers electricity generation modules based on Organic Rankine Cycle technology. The company was founded in 2008 and is headquartered in Munich, Germany.

ROMO Wind AG provides products that focus on improving the wind turbine rotor function. It offers wind farm optimization, and yaw and pitch correction services. The firm also provides iSpin1, a retrofit product that is used for accurate detection and subsequent one-off correction of static or average wind turbine yaw misalignments. The company was founded by Soren Mouritsen, Poul Anker Lubker and Jan Nikolaisen in 2011 and is headquartered in Zug, Switzerland.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany.

Part of Freepik Co. SL, EyeEm Ltd. is a British company that provides business support services. The company is based in Birmingham, UK. EyeEm was founded in 2011.

Dren Bio, Inc. operates as a biotechnology company. It focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents. The company was founded by John Wesley and Nenad Tomasevic in 2019 and is headquartered in San Carlos, CA.

Part of Equal 1 Laboratories Ireland Ltd., Equal1 Labs is a technology company that specializes in developing desktop quantum computers with unmatched performance, affordability, and energy efficiency. The company is based in Fremont, CA, and the CEO of the company is Dirk Leipold. The company's groundbreaking quantum processors integrate an entire quantum system onto a single chip, including millions of spin qubits, measurement and control microelectronics, AI-powered real-time error correction, and high-speed input/output.

River 2 Renal Corp. develops novel therapies targeting orphan diseases in the renal space. The private company is based in New York, NY.